Phototherapy in Persons With Multiple Sclerosis

NCT ID: NCT02365259

Last Updated: 2015-02-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-01-31

Study Completion Date

2016-02-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The current study examines the effect of phototherapy equipped with Narrow Band UVB lamps on vitamin D production in persons with MS.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Participants will be exposed to phototherapy according to the 2014 Guidelines issued by the American Academy of Dermatology 3 days per week over an 8-week period.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Sclerosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Phototherapy

This arm involves exposure to a UVB phototherapy device 3 times per week over 8 weeks.

Group Type EXPERIMENTAL

Phototherapy

Intervention Type DEVICE

Participants will be exposed to phototherapy according to the 2014 Guidelines issued by the American Academy of Dermatology 3 days per week over an 8-week period.

Shame phototherapy

This arm is identical with experimental arm, except that participants will be exposed to non-UVB florescent light.

Group Type PLACEBO_COMPARATOR

Phototherapy

Intervention Type DEVICE

Participants will be exposed to phototherapy according to the 2014 Guidelines issued by the American Academy of Dermatology 3 days per week over an 8-week period.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Phototherapy

Participants will be exposed to phototherapy according to the 2014 Guidelines issued by the American Academy of Dermatology 3 days per week over an 8-week period.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Female with multiple sclerosis

Exclusion Criteria

* Inability to stand still in a stabilized fashion without risk of falling for up to 6 minutes
* Known medical history of calcium disorder or knowledge of high calcium levels
* Known medical history of hyper-parathyroidism
* Current supplementation with oral vitamin D
* Known allergy to vitamin D
* History of cancer of any type including but not limited to skin cancer
* Obesity defined as BMI \> 30
* Known history of fat malabsorption conditions (i.e., steatorrhea)
* Current use of anti-epileptic medication
* Current use of glucocorticoids
* Fitzpatrick skin types I and VI using the Fitzpatrick skin type analysis
* Recent use of tanning facilities
Minimum Eligible Age

18 Years

Maximum Eligible Age

64 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Illinois at Urbana-Champaign

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Robert W Motl, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Illinois at Urbana-Champaign

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Exercise Neuroscience Research Laboratory

Urbana, Illinois, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

15178

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Vitamin D3 and the Stress-axis in MS
NCT02096133 TERMINATED PHASE2